miR-6883 LNPs / SMURF-Therapeutics - LARVOL DELTA

The immune dysregulation landscape and dynamic regulation of competing endogenous RNAs in spinal cord injury. (PubMed, Front Immunol) - "Six differentially expressed miRNAs were identified in SCI patients: four upregulated (hsa-miR-3680-5p, hsa-miR-410-3p, hsa-miR-6883-3p, hsa-miR-4508) and two downregulated (hsa-miR-3685, hsa-miR-6798-3p)...We constructed an immune-related ceRNA network in SCI, identifying six core miRNAs that regulate immune pathways and astrocyte-macrophage interactions. These findings provide new insights into SCI pathogenesis and potential therapeutic targets."

Journal • CNS Disorders • Inflammation • Orthopedics • BACH2 • MAP2K6 • MIR410 • PRKCH

Combination of CDK4/6 inhibitory and anti-hypoxia miRNA-6883 lipid nanoparticles with ferroptosis inducers or MEK inhibitors in preclinical breast and colorectal cancer models (AACR 2026) - "Accordingly, miR-6883 LNPs sensitized cells to doses of RSL3, erastin, or trametinib that were ineffective as monotherapies.ConclusionsOur data support the anti-hypoxia and antiproliferative activity of miR-6883, and provide a basis for combination therapies with ferroptosis inducers or MEKi. Future experiments will employ BC xenografts and assess long-term tumor growth inhibition of combination therapies."

Preclinical • Breast Cancer • Colorectal Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • HIF1A • SMURF2

Optimization of miRNA-6883 lipid nanoparticles for targeted CDK4/6 and HIF1a inhibition in colorectal and breast cancer cells (AACR 2025) - "Our DOE identified candidate miR-6883-LNP formulations for further optimization. Future work will assess the optimized miR-LNP therapeutic in murine models of colorectal and breast cancer. Currently, we are generating antibody-conjugated LNPs, with the aim of increasing potency and mitigating off target toxicity, and are continuing LNP optimization for in vivo studies."

Breast Cancer • Colorectal Cancer • Oncology • Solid Tumor • CDK4 • CDK6 • HIF1A